The ulcerative colitis (UC) therapy market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz / Xeljanz XR) for moderate to severe disease, together with emerging agents with novel MOAs and a general increase in the use of targeted therapies, will drive market growth. In particular, the availability of non-TNF biologics (e.g., Takeda’s Entyvio, Janssen’s Stelara) and the oral Jak inhibitor Xeljanz / Xeljanz XR will expand physicians’ treatment armamentarium and intensify market competition. Offsetting this growth will be the continued generic erosion of conventional agents and the entry of and increased physician comfort prescribing less-expensive biosimilars, factors that will pose hurdles to the uptake of emerging therapies.

QUESTIONS ANSWERED

  • What are the similarities and differences in the treatment of UC by U.S., European, and Japanese gastroenterologists?
  • How do gastroenterologists perceive biosimilar agents, and what has been/will be their impact on the UC therapy market?
  • What are KOLs’ insights into current treatment options (e.g., Pfizer’s Xeljanz / Xeljanz XR, Janssen’s Stelara)? What factors drive their treatment decisions?
  • What are KOLs’ perceptions of key emerging therapies (e.g., AbbVie’s upadacitinib and risankizumab, Janssen's guselkumab, Bristol Myers Squibb’s ozanimod, Arena’s etrasimod), and where do they see these agents fitting into the treatment algorithm?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Ulcerative Colitis - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Ritesh Gupta, PhD; Abey John, MPH

Ritesh Gupta is a Lead Analyst on the immune and inflammatory disorders team at Decision Resources Group, whose work focuses primarily on Psoriatic Arthritis, Ulcerative Colitis and Crohn’s Disease.

He holds a Ph.D. degree in Cell Biology from Max Delbrück Center for Molecular Medicine, Berlin, where he worked on development of novel inhibitors for HGF/MET signaling pathways. Prior to joining DRG, Ritesh has worked as an assistant manager with BioXcel corporation and provided insights on various consulting projects. He was also associated with GVK Biosciences and worked on drug repurposing projects.

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.

Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.


Related Reports

Ulcerative Colitis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) Dashboard

Ulcerative colitis (UC) is a chronic inte...

View Details

Ulcerative Colitis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) 2020

Ulcerative colitis (UC) is a chronic inte...

View Details

Ulcerative Colitis - Unmet Need - Detailed, Expanded Analysis (US & EU)

The moderate to severe ulcerative colitis (UC) drug market still offers substantial opportunity for companies that can address the remaining unmet needs in t...

View Details

Ulcerative Colitis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) – Pediatric

MARKET OUTLOOKConventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative colitis...

View Details